ASLN Stock Overview
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ASLAN Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$4.69 |
| 52 Week Low | US$0.39 |
| Beta | 1.47 |
| 1 Month Change | -28.21% |
| 3 Month Change | -18.43% |
| 1 Year Change | -88.82% |
| 3 Year Change | -97.18% |
| 5 Year Change | -97.46% |
| Change since IPO | -98.33% |
Recent News & Updates
Shareholder Returns
| ASLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | 1.5% | 1.2% |
| 1Y | -88.8% | 1.1% | 24.7% |
Price Volatility
| ASLN volatility | |
|---|---|
| ASLN Average Weekly Movement | 53.7% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 35 | Carl Alan Jason Firth | aslanpharma.com |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte.
ASLAN Pharmaceuticals Limited Fundamentals Summary
| ASLN fundamental statistics | |
|---|---|
| Market cap | US$10.61m |
| Earnings (TTM) | -US$44.22m |
| Revenue (TTM) | US$12.00m |
0.9x
P/S Ratio-0.2x
P/E RatioIs ASLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASLN income statement (TTM) | |
|---|---|
| Revenue | US$12.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$12.00m |
| Other Expenses | US$56.22m |
| Earnings | -US$44.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.95 |
| Gross Margin | 100.00% |
| Net Profit Margin | -368.50% |
| Debt/Equity Ratio | -200.2% |
How did ASLN perform over the long term?
See historical performance and comparison